Open access
291
Views
21
CrossRef citations to date
0
Altmetric
Review
Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties
William Montgomery1 Global Health Outcomes, Eli Lilly and Company, Sydney, AustraliaCorrespondence[email protected]
, Tamas Treuer2 Emerging Markets Business Unit (Neuroscience), Eli Lilly and Company, Budapest, Hungary
, Jamie Karagianis3 Eli Lilly and Company, Indianapolis, IN, USA
, Haya Ascher-Svanum4 Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, USA
& Gavan Harrison5 Asia-Pacific Medical Communications, Eli Lilly and Company, Sydney, Australia
Pages 109-125
|
Published online: 01 Feb 2012
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.